BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 26329495)

  • 1. Measurement of [123I]FP-CIT binding to the dopamine transporter (DAT) in healthy mouse striatum using dedicated small animal SPECT imaging: feasibility, optimization and validation.
    Greco A; Zannetti A; Pappatà S; Albanese S; Coda AR; Ragucci M; Nardelli A; Brunetti A; Cuocolo A; Salvatore M
    Q J Nucl Med Mol Imaging; 2018 Mar; 62(1):112-117. PubMed ID: 26329495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia.
    Gil-Navarro S; Lomeña F; Cot A; Lladó A; Montagut N; Castellví M; Bosch B; Rami L; Antonell A; Balasa M; Pavia J; Iranzo A; Molinuevo JL; Sánchez-Valle R
    Eur J Neurol; 2013 Nov; 20(11):1459-e126. PubMed ID: 23679075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.
    Di Giuda D; Calcagni ML; Totaro M; Cocciolillo F; Piano C; Soleti F; Fasano A; Cioni B; Bentivoglio AR; Giordano A
    Nucl Med Commun; 2012 Sep; 33(9):933-40. PubMed ID: 22735298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of dopamine transporter blockade by methylphenidate: first in vivo investigation using [123I]FP-CIT and a dedicated small animal SPECT.
    Nikolaus S; Wirrwar A; Antke C; Arkian S; Schramm N; Müller HW; Larisch R
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):308-13. PubMed ID: 15791440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I.
    Ziebell M; Holm-Hansen S; Thomsen G; Wagner A; Jensen P; Pinborg LH; Knudsen GM
    J Nucl Med; 2010 Dec; 51(12):1885-91. PubMed ID: 21078806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys.
    Booij J; Andringa G; Rijks LJ; Vermeulen RJ; De Bruin K; Boer GJ; Janssen AG; Van Royen EA
    Synapse; 1997 Nov; 27(3):183-90. PubMed ID: 9329154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.
    Booij J; Speelman JD; Horstink MW; Wolters EC
    Eur J Nucl Med; 2001 Mar; 28(3):266-72. PubMed ID: 11315592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease.
    Andringa G; Drukarch B; Bol JG; de Bruin K; Sorman K; Habraken JB; Booij J
    Neuroimage; 2005 Jul; 26(4):1150-8. PubMed ID: 15908232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An
    Joling M; Vriend C; Raijmakers PGHM; van der Zande JJ; Lemstra AW; Berendse HW; Booij J; van den Heuvel OA
    Neuroimage Clin; 2019; 22():101755. PubMed ID: 30884365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of [123I]FP-CIT binding to the dopamine transporter in the striatum of tree shrews by quantitative in vitro autoradiography.
    Geisler S; Beindorff N; Cremer M; Hoffmann K; Brenner W; Cumming P; Meyer PT; Langen KJ; Fuchs E; Buchert R
    Synapse; 2015 Oct; 69(10):497-504. PubMed ID: 26126942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of striatal dopamine transporter function in rats by in vivo beta-[123I]CIT pinhole SPECT.
    Scherfler C; Donnemiller E; Schocke M; Dierkes K; Decristoforo C; Oberladstätter M; Kolbitsch C; Zschiegner F; Riccabona G; Poewe W; Wenning G
    Neuroimage; 2002 Sep; 17(1):128-41. PubMed ID: 12482072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated administration of D-amphetamine induces loss of [123I]FP-CIT binding to striatal dopamine transporters in rat brain: a validation study.
    Booij J; de Bruin K; Gunning WB
    Nucl Med Biol; 2006 Apr; 33(3):409-11. PubMed ID: 16631090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects.
    Booij J; de Jong J; de Bruin K; Knol R; de Win MM; van Eck-Smit BL
    J Nucl Med; 2007 Mar; 48(3):359-66. PubMed ID: 17332612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism.
    Mateos JJ; Lomeña F; Parellada E; Font M; Fernandez E; Pavia J; Prats A; Pons F; Bernardo M
    Psychopharmacology (Berl); 2005 Sep; 181(2):401-6. PubMed ID: 15830229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT.
    Neishi H; Ikawa M; Okazawa H; Tsujikawa T; Arishima H; Kikuta KI; Yoneda M
    Eur Neurol; 2017; 78(3-4):161-168. PubMed ID: 28848099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in camera-specific variability in [(123)I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls.
    Buchert R; Kluge A; Tossici-Bolt L; Dickson J; Bronzel M; Lange C; Asenbaum S; Booij J; Atay Kapucu LÖ; Svarer C; Koulibaly PM; Nobili F; Pagani M; Sabri O; Sera T; Tatsch K; Vander Borght T; Van Laere K; Varrone A; Iida H
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1323-36. PubMed ID: 26816194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.